<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01343381</url>
  </required_header>
  <id_info>
    <org_study_id>CANNeCTIN</org_study_id>
    <nct_id>NCT01343381</nct_id>
  </id_info>
  <brief_title>Comparison of Heparin Types; Efficacy and Safety</brief_title>
  <official_title>Anticoagulant Effect and Reversal of Hepalean Compared With PPC Heparin in Patients Undergoing Cardiopulmonary Bypass: a Pilot Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin, a blood thinner, is used routinely in Open-heart surgery. Do different brands of
      this drug have differing clinical effects despite both having exactly the same regulation and
      marketing specifications?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility to conduct a larger trial</measure>
    <time_frame>pre-cardiopulmonary bypass initiation; peri-operative period (in minutes) to 24 hours post-operatively</time_frame>
    <description>Will the pilot show that the pilot's design is feasible with respect to timely patient enrolment, blinding of treatment allocation, study drug dosage requirements and the collection and measurement of study outcomes; ACT of &gt; 450 seconds after initial pre-CPB heparin bolus, dosage of additional heparin (if any) to maintain an ACT of greater than 450 seconds, differences (if any) in coagulation profiles, differences if any in chest tube drainage, differences (if any) in post-operative transfusion requiements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACT after initial dose of heparin</measure>
    <time_frame>pre-cardiopulmonary bypass initiation; peri-operatively(in seconds)</time_frame>
    <description>A dose of 400 units/kgm will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Heparin Dose used</measure>
    <time_frame>pre-cardiopulmonary bypass initiation to termination of cardiopulmonary bypass; peri-operatively(in minutes)</time_frame>
    <description>The total dose of heparin needed to maintain an ACT of 480 seconds throught bypass time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation</measure>
    <time_frame>post-cardiopulmonary inition, at the 45 minute on pump time point; perioperatively to 24 hours post-operatively</time_frame>
    <description>aPTT, TCT, anti-Xa and anti IL IIa activity ant TAT levels after initial heparin dose and after 45 minutes on CPB.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Hepalean Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PPC Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalean Heparin</intervention_name>
    <description>400 units per kilogram bolus prior to initiation of CPB</description>
    <arm_group_label>Hepalean Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPC Heparin</intervention_name>
    <description>400 unit per kilogram bolus prior to initiation of CPB</description>
    <arm_group_label>PPC Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  will be undergoing cardiopulmonary bypass for coronary artery disease

          -  has provided written informed consent

        Exclusion Criteria:

          -  Allergy or intolerance to Heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin H Teoh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences: Hamilton General Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences: Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2011</study_first_submitted>
  <study_first_submitted_qc>April 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2011</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heparin</keyword>
  <keyword>Coronary artery bypass graft surgery</keyword>
  <keyword>Anti-coagulation efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

